• Diagnosis and treatment recommendations for C. difficile and other enteric infections
• Access to microbiome replacement therapies including Vowst (fecal microbiota spores live-brpk) and Rebyota (fecal microbiota live-jslm); we can offer administration of Rebyota either on-campus or via linkages to the home infusion program. In select cases, traditional fecal microbiota transplant may be offered if supply is available.
• Access to Bezlotoxumab infusion at one of our clinic locations (East Baltimore or Green Spring Station campuses)
• Connection to clinical trials of novel microbiome replacement therapies
• Access to participation in non-clinical-trial research projects
• Referrals to gastroenterology or dietitian services
  
   

This clinic serves patients with difficult-to-treat C. difficile infections, particularly those that have come back despite courses of antibiotics. If you are referred to our clinic, we will review your diagnosis, recommend additional testing or treatment if needed, and discuss whether you are a candidate for microbiome replacement therapy (of which there are now multiple options including oral and enema-based therapies) and/or Bezlotoxumab (Zinplava), an immune-based therapy. The providers who work in our clinic may also be able to enroll you in cutting-edge clinic trials for other microbiome replacement therapies. While you will be seen by an infectious diseases provider during your visit, we maintain close collaborations with gastroenterologists and dietitians to whom you can be referred if needed.